 Rebecca Scalzo
Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiorespiratory Fitness | 4 | 2025 | 74 | 2.010 |
Why?
| | Diabetes Mellitus, Type 2 | 12 | 2025 | 2588 | 1.710 |
Why?
| | Exercise | 10 | 2025 | 2198 | 1.150 |
Why?
| | Aromatase Inhibitors | 2 | 2025 | 78 | 1.040 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2025 | 34 | 0.950 |
Why?
| | Cancer Survivors | 2 | 2025 | 337 | 0.760 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2021 | 62 | 0.680 |
Why?
| | Oxygen Consumption | 6 | 2025 | 718 | 0.640 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2021 | 193 | 0.630 |
Why?
| | Insulin Resistance | 3 | 2025 | 1244 | 0.610 |
Why?
| | Physical Endurance | 3 | 2015 | 279 | 0.600 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 31 | 0.590 |
Why?
| | Mitochondria, Muscle | 3 | 2018 | 120 | 0.590 |
Why?
| | Hypoxia | 3 | 2015 | 1199 | 0.580 |
Why?
| | Leg | 1 | 2021 | 242 | 0.580 |
Why?
| | Vascular Stiffness | 3 | 2023 | 486 | 0.570 |
Why?
| | Diastole | 1 | 2019 | 146 | 0.570 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 46 | 0.570 |
Why?
| | Rats, Wistar | 5 | 2024 | 450 | 0.570 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2025 | 394 | 0.570 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 88 | 0.530 |
Why?
| | Weight Gain | 1 | 2021 | 561 | 0.530 |
Why?
| | Performance-Enhancing Substances | 1 | 2017 | 11 | 0.520 |
Why?
| | Breast Neoplasms | 3 | 2025 | 2382 | 0.520 |
Why?
| | Sex Characteristics | 4 | 2023 | 782 | 0.510 |
Why?
| | Adipose Tissue | 1 | 2021 | 645 | 0.500 |
Why?
| | Carotid Arteries | 1 | 2018 | 208 | 0.500 |
Why?
| | Venoms | 1 | 2016 | 22 | 0.490 |
Why?
| | Metformin | 2 | 2017 | 329 | 0.490 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2016 | 34 | 0.480 |
Why?
| | Sympatholytics | 2 | 2015 | 11 | 0.480 |
Why?
| | Clonidine | 2 | 2015 | 33 | 0.480 |
Why?
| | Aorta | 2 | 2018 | 440 | 0.470 |
Why?
| | Methazolamide | 1 | 2015 | 5 | 0.470 |
Why?
| | Aminophylline | 1 | 2015 | 12 | 0.470 |
Why?
| | Physical Conditioning, Animal | 1 | 2018 | 242 | 0.470 |
Why?
| | Athletic Performance | 1 | 2017 | 78 | 0.470 |
Why?
| | Altitude | 2 | 2017 | 463 | 0.460 |
Why?
| | Adipose Tissue, White | 2 | 2024 | 43 | 0.460 |
Why?
| | Adaptation, Physiological | 2 | 2018 | 560 | 0.430 |
Why?
| | Diabetic Angiopathies | 1 | 2016 | 264 | 0.420 |
Why?
| | Muscle, Skeletal | 7 | 2023 | 1789 | 0.400 |
Why?
| | Adipose Tissue, Brown | 1 | 2014 | 60 | 0.400 |
Why?
| | Fibronectins | 1 | 2014 | 136 | 0.390 |
Why?
| | Tamoxifen | 3 | 2023 | 191 | 0.370 |
Why?
| | Muscle Proteins | 1 | 2014 | 242 | 0.360 |
Why?
| | Obesity | 3 | 2023 | 3116 | 0.340 |
Why?
| | Running | 1 | 2014 | 233 | 0.340 |
Why?
| | Peptides | 1 | 2016 | 998 | 0.320 |
Why?
| | Hypoglycemic Agents | 2 | 2019 | 1399 | 0.320 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 209 | 0.260 |
Why?
| | Rats | 4 | 2024 | 5584 | 0.240 |
Why?
| | Iodide Peroxidase | 1 | 2026 | 35 | 0.230 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2025 | 50 | 0.230 |
Why?
| | Exercise Tolerance | 2 | 2018 | 283 | 0.220 |
Why?
| | Male | 18 | 2026 | 72842 | 0.210 |
Why?
| | Accelerometry | 1 | 2025 | 118 | 0.210 |
Why?
| | Female | 16 | 2026 | 78844 | 0.210 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2025 | 214 | 0.210 |
Why?
| | Humans | 22 | 2026 | 145474 | 0.210 |
Why?
| | Overweight | 2 | 2025 | 614 | 0.200 |
Why?
| | Ovariectomy | 1 | 2024 | 166 | 0.190 |
Why?
| | Adult | 10 | 2025 | 40777 | 0.190 |
Why?
| | Sucrose | 1 | 2023 | 114 | 0.190 |
Why?
| | Blood Glucose | 3 | 2025 | 2341 | 0.190 |
Why?
| | Double-Blind Method | 2 | 2019 | 2062 | 0.190 |
Why?
| | Exercise Test | 2 | 2015 | 630 | 0.180 |
Why?
| | Follicle Stimulating Hormone | 1 | 2024 | 266 | 0.180 |
Why?
| | Ventricular Function, Left | 1 | 2025 | 542 | 0.180 |
Why?
| | Diet, High-Fat | 1 | 2023 | 266 | 0.180 |
Why?
| | Sympathetic Nervous System | 2 | 2014 | 181 | 0.180 |
Why?
| | Insulin | 3 | 2023 | 2512 | 0.180 |
Why?
| | Insulins | 1 | 2022 | 38 | 0.170 |
Why?
| | Mice, Obese | 1 | 2021 | 68 | 0.170 |
Why?
| | Vasodilation | 3 | 2022 | 521 | 0.170 |
Why?
| | Dietary Fats | 1 | 2023 | 308 | 0.170 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2023 | 382 | 0.170 |
Why?
| | Thinness | 1 | 2021 | 100 | 0.170 |
Why?
| | Animals | 10 | 2026 | 38030 | 0.170 |
Why?
| | Myocytes, Cardiac | 1 | 2026 | 546 | 0.170 |
Why?
| | Cardiovascular Diseases | 2 | 2023 | 2187 | 0.160 |
Why?
| | Pulse Wave Analysis | 2 | 2023 | 267 | 0.160 |
Why?
| | Estradiol | 1 | 2024 | 515 | 0.160 |
Why?
| | Glucose | 3 | 2022 | 1048 | 0.160 |
Why?
| | Vasoconstriction | 2 | 2018 | 216 | 0.160 |
Why?
| | Vascular Diseases | 1 | 2022 | 252 | 0.150 |
Why?
| | Aged | 6 | 2025 | 26153 | 0.150 |
Why?
| | Sulfonylurea Compounds | 1 | 2019 | 51 | 0.140 |
Why?
| | Placebos | 1 | 2019 | 193 | 0.140 |
Why?
| | Pterins | 1 | 2018 | 7 | 0.140 |
Why?
| | Myocardial Infarction | 1 | 2026 | 1210 | 0.130 |
Why?
| | Energy Metabolism | 1 | 2024 | 935 | 0.130 |
Why?
| | Glycogen | 1 | 2017 | 55 | 0.130 |
Why?
| | Mitochondria, Heart | 1 | 2018 | 107 | 0.130 |
Why?
| | Blood Vessels | 1 | 2018 | 167 | 0.130 |
Why?
| | Ventricular Fibrillation | 1 | 2017 | 64 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5904 | 0.120 |
Why?
| | Middle Aged | 5 | 2025 | 36215 | 0.120 |
Why?
| | Oxyhemoglobins | 1 | 2015 | 28 | 0.110 |
Why?
| | Young Adult | 5 | 2015 | 14218 | 0.110 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2016 | 149 | 0.110 |
Why?
| | Healthy Volunteers | 1 | 2015 | 219 | 0.110 |
Why?
| | Arteries | 1 | 2016 | 261 | 0.110 |
Why?
| | Mice, Inbred C57BL | 2 | 2026 | 5983 | 0.110 |
Why?
| | Seals, Earless | 1 | 2014 | 5 | 0.110 |
Why?
| | Endothelium, Vascular | 2 | 2022 | 956 | 0.110 |
Why?
| | Diving | 1 | 2014 | 7 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 693 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2021 | 1356 | 0.100 |
Why?
| | Deuterium Oxide | 1 | 2014 | 20 | 0.100 |
Why?
| | Physical Education and Training | 1 | 2014 | 70 | 0.100 |
Why?
| | Physical Conditioning, Human | 1 | 2014 | 38 | 0.100 |
Why?
| | Blood Pressure | 2 | 2021 | 1779 | 0.090 |
Why?
| | Quadriceps Muscle | 1 | 2014 | 120 | 0.090 |
Why?
| | Cell Respiration | 3 | 2018 | 105 | 0.090 |
Why?
| | Oxygen | 1 | 2018 | 978 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1044 | 0.090 |
Why?
| | Fibroblast Growth Factors | 1 | 2014 | 188 | 0.090 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 263 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2016 | 756 | 0.090 |
Why?
| | Heart Rate | 1 | 2015 | 855 | 0.080 |
Why?
| | Risk Factors | 1 | 2025 | 10885 | 0.080 |
Why?
| | Mice | 3 | 2026 | 18329 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5423 | 0.060 |
Why?
| | Triiodothyronine | 1 | 2026 | 54 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2026 | 68 | 0.060 |
Why?
| | Ovary | 1 | 2024 | 233 | 0.040 |
Why?
| | Nitric Oxide Synthase | 1 | 2022 | 234 | 0.040 |
Why?
| | Longevity | 1 | 2022 | 178 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 286 | 0.040 |
Why?
| | Transgenes | 1 | 2021 | 190 | 0.040 |
Why?
| | Estrogens | 1 | 2023 | 367 | 0.040 |
Why?
| | Glutathione | 1 | 2022 | 370 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 2121 | 0.040 |
Why?
| | Body Composition | 1 | 2024 | 693 | 0.040 |
Why?
| | Body Weight | 1 | 2024 | 971 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 611 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2026 | 3124 | 0.030 |
Why?
| | Carbohydrates | 1 | 2018 | 66 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3623 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2022 | 892 | 0.030 |
Why?
| | Transcriptome | 1 | 2024 | 1038 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 707 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 360 | 0.030 |
Why?
| | Citrate (si)-Synthase | 1 | 2017 | 57 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 172 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2188 | 0.030 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2017 | 192 | 0.030 |
Why?
| | Myocardial Ischemia | 1 | 2017 | 285 | 0.030 |
Why?
| | Liver | 1 | 2024 | 1896 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2017 | 500 | 0.030 |
Why?
| | Swine | 1 | 2017 | 825 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2018 | 475 | 0.020 |
Why?
| | Mitochondria | 1 | 2018 | 992 | 0.020 |
Why?
| | Fatty Acids | 1 | 2014 | 457 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1067 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1707 | 0.020 |
Why?
| | Signal Transduction | 1 | 2018 | 5216 | 0.010 |
Why?
| | Adolescent | 1 | 2022 | 22529 | 0.010 |
Why?
|
|
Scalzo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|